If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Benchmarking Reports » Medical Affairs » Medical Affairs Excellence
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Download FREE Excerpt
Industries Profiled: Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Medical Device; Consumer Products; Diagnostic Companies Profiled: Astellas; UCB Pharma; Onyx Pharmaceuticals; Upsher-Smith; Lilly; ViiV Healthcare; Purdue Pharma; Xenoport; Insys Therapeutics; Sanofi; Lundbeck; Theravance; Boehringer Ingelheim; Medunik Canada; Ipsen; Merck; Axon Pharma; Merz Pharma; Janssen; Baxter Healthcare; Jazz Pharmaceuticals; Amgen; Eisai; Bayer Healthcare; AstraZeneca; Biogen Idec
Study Snapshot This study engaged 29 executives from 26 leading life sciences companies. Segmentation analysis was key to examining trends and effective practices. 11 participants make up the Large Companies Segment, while the Mid-Size Companies Segment consists of 10 participants and Small Companies Segment consists of 8 participants.
Key Findings 1. Scientific Publication Metrics: Sixty percent of the benchmark class thinks that % publications in top-tier journals is a highly effective metric. In addition, more than 40% of the participants agree that % papers and publications accepted is highly effective to evaluate scientific publication performance.